Office: South San Francisco, CA

Executive Assistant:
Christine Esguerra
(650) 238-5055

William Young
Venture Partner

Mr. Young joined Clarus in 2010 as a Venture Partner from Monogram Biosciences, a leader in personalized medicine, where he served as chief executive officer from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young currently serves on the Board of Directors of Vertex (NASDAQ: VRTX) and is the lead director at Theravance (NASDAQ:TBPH). Previously he was Chairman of the Board of Biogen IDEC (NASDAQ: BIIB). Prior to Monogram he was at Genentech since 1980 at positions of increasing responsibility, including chief operating officer responsible for all of the biotechnology company's development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years.

Mr. Young received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.

Mr. Young represents Clarus on the Board of Directors of Praxis Medicine, and is the Chairman of the Board of Annexon Biosciences and Nanostring (NASDAQ: NSTG). Previous directorships include Tyrx (acquired by Medtronic).

Clarus Board Seats

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: William Young
Dennis Henner
Emmett Cunningham

Annexon Biosciences

Annexon is developing novel antibody therapeutics for neurodegenerative and autoimmune disorders. Annexon’s most advanced program targets Huntington’s disease

Annexon Website

Fund: Clarus Lifesciences II, L.P.
Sector: Diagnostics & Tools
Type: Public
Team: Scott Requadt
William Young
Nicholas Galakatos

NanoString Technologies, Inc. (NASDAQ: NSTG)

Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.

NanoString Website

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Type: Private
Team: Scott Requadt
William Young

TyRx acquired by Medtronic, Inc. in January 2014

TyRx develops and commercializes proprietary, polymer-based, antibiotic-eluting medical products that prevent infection and capsular scar formation, two common morbidities associated with medical device implants.It currently has 3 FDA approved products including AIGIS CRMD, an antibiotic-eluting mesh envelope to prevent infections associated with the implantation of cardiac rhythm management devices (CRMDs) such as pacemakers and implantable defibrillators. The company launched AIGIS CRMD in the US in Q3 2008 with its own specialty sales force.

TyRx Website